Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATIONAL Platform Trial for infection prevention in blood cancers
ACTRN12624000961549Phase 3Recruiting
- Sponsor
- Monash University
- Start
- Apr 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polyvalent human immunoglobulin in hematopoietic malignancies and hypogammaglobulinemia (3 arms), sponsored by Monash University. Primary endpoint: Event-free survival. Started Apr 2025; status: recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
hematopoietic malignancieshypogammaglobulinemia
Beyond the preview
Go deeper on ACTRN12624000961549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000961549.